Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes
Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist. Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) risk by reducing major adverse cardiovascular events in type 2 diabetes patients. Strong preclinical evidence suppor...
Main Authors: | Angelo Maria Patti, Rosaria Vincenza Giglio, Alberto Allotta, Andreina Bruno, Tommaso Di Bella, Anca Pantea Stoian, Marcello Ciaccio, Manfredi Rizzo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/5/1362 |
Similar Items
-
Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
by: Evgenia Koureta, et al.
Published: (2024-02-01) -
Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
by: Ali A. Rizvi, et al.
Published: (2021-10-01) -
The Role of Advanced Glycation End Products on Dyslipidemia
by: Jelena Vekic, et al.
Published: (2023-01-01) -
Subclinical Atherosclerosis Progression in Obese Children with Relevant Cardiometabolic Risk Factors Can Be Assessed through Carotid Intima Media Thickness
by: Monica-Simina Mihuta, et al.
Published: (2021-11-01) -
Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents
by: Jelena Vekic, et al.
Published: (2021-11-01)